Source comparison
BPC-157 for Hip Bursitis Research: Comparison Table
Corticosteroid Injection Suppresses inflammatory cytokines (IL-1, TNF-α) 1–3 weeks symptom relief None. May inhibit collagen synthesis Repeat injections increase tendon rupture risk; temporary effect only Standard care but no repair mechanism NSAIDs (oral) Inh
This comparison does not assign a generated winner or score.
- Corticosteroid Injection
- Suppresses inflammatory cytokines (IL-1, TNF-α)
- 1–3 weeks symptom relief
- None. May inhibit collagen synthesis
- Repeat injections increase tendon rupture risk; temporary effect only
- Standard care but no repair mechanism
- NSAIDs (oral)
- Inhibits COX enzymes, reducing prostaglandin synthesis
- Days to weeks
- None. Symptom control only
- GI side effects, cardiovascular risk with long-term use; doesn't address underlying tissue damage
- Effective for acute pain, ineffective for chronic structural issues
- Physical Therapy
- Restores biomechanics, reduces mechanical stress on bursa
- 6–12 weeks
- Indirect. Improved load distribution may reduce re-injury
- Requires patient compliance; ineffective if tissue integrity severely compromised
- Essential but insufficient alone for advanced cases
- BPC-157 (research peptide)
- Promotes angiogenesis (VEGF upregulation), modulates NO pathways, enhances collagen deposition
- Unknown in humans; 2–6 weeks in animal models
- High potential based on preclinical tendon/ligament repair studies
- No human clinical trials; dosing and safety unverified; regulatory status unclear
- Promising mechanistic profile but experimental. Requires rigorous study design
- PRP (Platelet-Rich Plasma)
- Delivers concentrated growth factors (PDGF, TGF-β, IGF-1) to injury site
- 4–8 weeks
- Moderate. Evidence mixed for bursitis specifically
- Variable preparation protocols affect efficacy; multiple injections often needed
- Established for tendinopathy, less clear for bursitis